KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Short term Debt (2016 - 2025)

Historic Short term Debt for Biogen (BIIB) over the last 14 years, with Q2 2025 value amounting to $150.0 million.

  • Biogen's Short term Debt changed N/A to $150.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $150.0 million, marking a year-over-year change of. This contributed to the annual value of $1.7 billion for FY2024, which is 106573.33% up from last year.
  • According to the latest figures from Q2 2025, Biogen's Short term Debt is $150.0 million.
  • In the past 5 years, Biogen's Short term Debt ranged from a high of $1.7 billion in Q4 2024 and a low of $150.0 million during Q4 2023
  • Over the past 4 years, Biogen's median Short term Debt value was $574.6 million (recorded in 2021), while the average stood at $761.9 million.
  • Within the past 5 years, the most significant YoY rise in Biogen's Short term Debt was 106573.33% (2024), while the steepest drop was 106573.33% (2024).
  • Over the past 4 years, Biogen's Short term Debt (Quarter) stood at $999.1 million in 2021, then plummeted by 84.99% to $150.0 million in 2023, then surged by 1065.73% to $1.7 billion in 2024, then plummeted by 91.42% to $150.0 million in 2025.
  • Its last three reported values are $150.0 million in Q2 2025, $1.7 billion for Q4 2024, and $150.0 million during Q4 2023.